Abstracts Archive - Page 160 of 2607 - ACR Meeting Abstracts

Abstract Number: 0891 • ACR Convergence 2025
MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter, randomized, controlled trial.
Maxime Samson¹, Abderrahmane Bourredjem², Rodérau Outh³, Vincent Grobost⁴, François Lifermann⁵, Guillaume DIREZ⁶, Emmanuel Ribeiro⁷, Eric Oziol⁸, Valerie Devauchelle⁹, Mikael Ebbo¹⁰, Nicolas Limal¹¹, Romain Paule¹², Boris Bienvenu¹³, Antoine Poulet¹³, Sébastien Miranda¹⁴, Ygal Benhamou¹⁴, Thomas Quemeneur¹⁵, Claire Dingremont¹⁶, Andre Ramon¹⁷, Bernard Simorre⁸, Quitterie Reynaud¹⁸, Christian AGARD¹⁹, Olivier Espitia²⁰, Arsène Mekinian²¹, Jean-François Alexandra²², Emilie Berthoux²³, Laurent Perard²³, Antoine Baudet²⁴, Rafik Mesbah²⁵, David Lacôte-Delarbre²⁶, Julien Stievenart²⁷, Marc André²⁷, Jean Sébastien Allain²⁸, Rolland Jaussaud²⁹, Julie Magnant³⁰, Amélie Servettaz³¹, Hubert De Boysson³², Marc Ruivard⁴, Benjamin Terrier³³, Alexis REGENT³⁴, Amélie Cransac³⁵, Isabelle Fournel³⁶, Hervé Devilliers³⁶ and Bernard Bonnotte³⁷, ¹CHU Dijon Bourgogne, Dijon, France, ²Centre d'Investigation Clinique, CHU Dijon, Dijon, France ; INSERM, CIC ¹⁴³², Module Epidémiologie Clinique, Dijon, France, ³Department of Internal Medicine, Centre Hospitalier de Perpignan, Perpignan, France., Clermont-Ferrand, France, ⁴Internal medicine, CHU Clermont Ferrand Estaing, Clermont Ferrand, France, ⁵Internal Medicine, CH de Dax, Dax, France, ⁶Rheumatology, CH Le Mans, Le Mans, France, ⁷Internal medicine and clinical immunology, CHU Bordeaux, Hôpital Saint-André, Bordeaux, France, ⁸Internal Medicine, CH Bézier, Bézier, France, ⁹UBO, Brest, France, ¹⁰Internal Medicine, Marseille-APHM, hôpital La Timone, Marseille, France, ¹¹Internal Medicine, CHU Henri Mondor, Créteil, France, ¹²Hospital Foch, Service de medicine interne, Suresnes, Paris, Suresnes, France, ¹³Internal Medicine, Hôpital Saint Joseph, Marseille, France, ¹⁴Internal Medicine, CHU Rouen, Rouen, France, ¹⁵Nephrology and Internal Medicine, CH Valenciennes, Valenciennes, France, ¹⁶Internal Medicine, Groupement hospitalier Tarbes-Lourdes, Tarbes, France, ¹⁷Rheumatology, Université Bourgogne Europe, CHU Dijon Bourgogne, Dijon, France, ¹⁸Internal medicine and vascular diseases, Hospices Civils de Lyon, Lyon, France, ¹⁹Internal medicine, Nantes University Hospital, Nantes, France, ²⁰CHU de Nantes, Nantes, France, ²¹Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ²²Internal Medicine, Hôpital Bichat, APHP, Paris, France, ²³Internal Medicine, Saint Luc Saint Joseph Hospital, Lyon, France, ²⁴Internal Medicine, CH Annecy, Annecy, France, ²⁵Nephrology, CH Boulogne sur Mer, Boulogne sur Mer, France, ²⁶Internal Medicine, Hôpital d’instruction des armées Saint Anne, Toulon, France, ²⁷Internal Medicine, CHU Clermont Ferrand Gabriel Montpied, Clermont Ferrand, France, ²⁸Internal Medicine and Clinical Immunology, CH Saint Malo, Saint Malo, France, ²⁹Internal Medicine and Clinical Immunology, CHU Nancy, Nancy, France, ³⁰Internal Medicine, CHU Tours, Tours, France, ³¹Internal Medicine, CHU Reims, Reims, France, ³²Internal Medicine, CHU Caean, Caen, France, ³³Cochin Hospital, Paris, France, ³⁴Hopital Cochin, Paris, France, ³⁵Pharmacy, CHU Dijon Bourgogne, Dijon, France, ³⁶Centre d'Investigation Clinique, CHU Dijon, Dijon, France ; INSERM, CIC ¹⁴³², Module Epidémiologie Clinique, Dijon, France, ³⁷Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France
Background/Purpose: This trial aimed to compare the efficacy and safety of methotrexate (MTX) vs. tocilizumab (TCZ), in combination with glucocorticoid (GC), in patients with giant…
Abstract Number: 0602 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Ami Vyas¹, Steven Cohen² and Christine Eisenhower², ¹University of Rhode Island, Kingston, RI, ²University of Rhode Island, Kingston
Background/Purpose: Limited information is available about the effect of systemic lupus erythematosus (SLE) on healthcare resource utilization and healthcare expenditures. The associations between SLE and…
Abstract Number: 0880 • ACR Convergence 2025
Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications
Nicholas landini¹, lisa Jungblut², cecilia strappa³, Christian Blüthgen², Rucsandra Dobrota⁴, Muriel Elhai⁵, Carina Mihai⁶, Sinziana Muraru-Carbune², Martina Orlandi⁷, mariaelena Occhipinti⁸, Khadija El-Aoufy⁹, Gemma Lepri¹⁰, valeria panebianco¹¹, anna rita larici³, Anna-Maria Hoffmann-Vold¹², Cosimo Nardi¹³, Serena Guiducci¹⁴, Silvia Bellando-Randone¹⁵, Marco Matucci-Cerinic¹⁶, Thomas Frauenfelder², Oliver Distler¹⁷ and Cosimo Bruni¹⁸, ¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ²Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ³Advanced Radiology Center, Department of Diagnostic Imaging and Oncological Radiotherapy, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy, rome, Italy, ⁴Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁵Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, Schlieren, Switzerland, ⁶University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ⁸Division of Radiology, Fondazione Toscana Gabriele Monasterio, Pisa, Italy., pisa, Italy, ⁹Department of Health Science, University of Florence, Florence, Italy., firenze, Italy, ¹⁰Department of Experimental and Clinical Medicine, University of Florence, Division of Rheumatology Scleroderma Unit, AOU Careggi Hospital, Florence, Italy., Florence, Italy, ¹¹Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy., Rome, Italy, ¹²Oslo University Hospital, Oslo, Norway, ¹³Department of Experimental and Clinical Biomedical Sciences, Radiodiagnostic Unit n. ², University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy, Florence, Italy, ¹⁴Department of Experimental and Clinical Medicine, Scleroderma Unit, Division of Rheumatology, University of Florence, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Pistoia, Italy, ¹⁵University of Florence, Florence, Florence, Italy, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹⁸University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of death in patients with systemic sclerosis (SSc), especially in case of extensive disease detected on…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 0609 • ACR Convergence 2025
Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes
Eleni Papachristodoulou¹ and Vasileios Kyttaris², ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
Background/Purpose: Neutropenia is a known hematologic manifestation of SLE, yet its clinical implications remain poorly defined. We conducted a retrospective study to characterize the frequency,…
Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Fadi Kharouf¹, JuanPablo Diaz Martinez², Pankti Mehta³, Dafna D. Gladman⁴, Laura Whitall Garcia⁵ and Zahi Touma⁶, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…
Abstract Number: 0608 • ACR Convergence 2025
Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients
Elena Heras Recuero¹, Antia Garcia Fernandez², Cristina Gomez-Moreno³, Ivan Ferraz Amaro⁴, Javier Llorca⁵ and Miguel A. González-Gay⁶, ¹Hospital Fundacion Jimenez Dias, Madrid, Spain, ²Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ³Fundacion Jiménez Díaz School of Nursing, Madrid, Autonomous University Madrid, Madrid, Spain, ⁴Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁵CIBER Epidemiología y Salud Pública (CIBERESP) and Department of Medical and Surgical Sciences, University of Cantabria, Santander, Spain, ⁶Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous…
Abstract Number: 0890 • ACR Convergence 2025
Granzyme K+ CD8 T cells colocalize with myeloid cells and activate them through several pathways
Julia Nicole Zeid¹, Kaitlyn Arce², Nanxi Guo¹, Kartik Bhamidipati³, Kevin Wei⁴, Larry Moreland⁵, Fan Zhang⁶ and Anna Helena Jonsson², ¹University of Colorado School of Medicine, Aurora, ²University of Colorado School of Medicine, Aurora, CO, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵University of Colorado, Denver, CO, ⁶The University of Colorado, Aurora, CO
Background/Purpose: Granzyme K (GZMK)-expressing CD8 T cells have recently been detected in tissues from an increasing number of autoimmune conditions, but their role in disease…
Abstract Number: 0865 • ACR Convergence 2025
Spatial Transcriptomic Analysis of Calcinosis Cutis in Dermatomyositis Uncovers Disease-Associated Pathways Involving IL-6, Tissue Remodeling, and Osteopontin
Cassie Parks¹, York Wang¹, Lisa Christopher-Stine², Jemima Albayda², Joel Sunshine³, Shira Ziegler¹ and Chris Mecoli¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: Calcinosis cutis affects up to 20% of adults with dermatomyositis (DM), causing significant morbidity including recurrent infections, incapacitating pain, and functional impairment. Current management…
Abstract Number: 0619 • ACR Convergence 2025
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Luciana Parente Costa Seguro¹, Andrea Negrini², Sandra G Pasoto³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro³, Eduardo Borba¹, Emily Figueiredo Neves Yuki⁵, Artur Sartori², Danieli Andrade⁶, Thiago Freitas⁷, Henrique Giardini⁷, Clovis Artur Silva⁸ and Eloisa Bonfa¹, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…
Abstract Number: 0551 • ACR Convergence 2025
Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
Victor Cazac¹ and Eugeniu Russu², ¹Norwalk Hospital, Nuvance Health, Connecticut, ²"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops insidiously from psoriasis (PsO), with enthesitis representing a critical initial site of inflammation. Musculoskeletal ultrasonography (MSUS) enables the identification of…
Abstract Number: 0863 • ACR Convergence 2025
Myeloid Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells
Raphael Kirou¹, Iago Pinal-Fernandez¹, Maria Casal-Dominguez¹, Katherine Pak¹, Chiseko Ikenaga², Christopher Nelke³, Stefania Dell'orso¹, Faiza Naz¹, Shamima Islam¹, Gustavo Gutierrez-Cruz¹, Werner Stenzel⁴, Albert Selva-O'Callaghan⁵, José Milisenda⁶ and Andrew Mammen⁷, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²The University of Tokyo, Tokyo, Japan, ³Heinrich Heine University of Düsseldorf, Düsseldorf, Germany, ⁴Charite University, Berlin, Germany, ⁵Hospital Universitari Vall d'Hebron, Barcelona, Spain, ⁶Hospital Clinic de Barcelona, Barcelona, Spain, ⁷NIH, Bethesda, MD
Background/Purpose: Although inclusion body myositis (IBM) is an inflammatory myopathy, there are no effective immunomodulating agents, underlying the need for better understanding of its pathogenesis.…
Abstract Number: 0605 • ACR Convergence 2025
The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort
Anubhav Singh¹, Rocío Gamboa-Cárdenas², Victor Pimentel-Quiroz³, Zoila Rodriguez-Bellido⁴, Cesar Pastor-Asurza⁵, Risto Perich-Campos⁶, Manuel Ugarte-Gil⁷ and Graciela Alarcón⁸, ¹Baptist hospital of southeast Texas, Beaumont, TX, ²Universidad Científica del Sur, Lima, Peru, ³Universidad Científica del Sur, San Isidro, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen, Lima, Pakistan, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷Universidad Cientifica del Sur, Lima, Peru, ⁸The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) was developed to ascertain frailty in systemic lupus erythematosus (SLE) patients. The aim of this…
Abstract Number: 0614 • ACR Convergence 2025
Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound
Ileana C. Reynosa-Silva¹, Oscar Azael Garza-Flores², Fernanda M. Garcia-Garcia³, Aleydis Gonzalez-Melendez¹, Iris J. Colunga-Pedraza³, Dionicio A. Galarza-Delgado³, Jose R Azpiri-Lopez⁴, Rosa Arvizu-Rivera⁵, Jesus Alberto Cardenas-de la Garza⁶ and Diego Azamat Salcedo Almanza⁷, ¹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Guadalupe, Mexico, ³Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁴Cardiology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, ⁶Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, ⁷Radiology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with an elevated risk of cardiovascular (CV) disease, largely due to chronic inflammation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].